Categories Uncategorized

Psychedelics Group Publishes Handbook Guiding Local Decriminalization Efforts

Decriminalize Nature, a national organization that advocates for psychedelics reform, recently introduced an extensive guideline for organizers who are interested in advocating for policy changes at a local level, which will lessen the criminalization of entheogenic substances.

The organization has supported other successful campaigns to make laws on fungi-and-plant derived psychedelics a low priority in law enforcement efforts from 3 cities. Decriminalize Nature wants to now provide activists with the resources they require to get psychedelic substances decriminalized, either through ballot initiatives or the legislative channel. The guidelines they released talk about the organization’s origin as well as its principles, objectives and the best practices to achieve their goals.

Organizers are not only encouraged to present model legislations to local lawmakers with the aim of advancing reform through legislatures and city councils but to also customize them to fit their community’s needs.

In the guidelines’ introduction, Decriminalize Nature states that their role is be available and present to support local efforts. The guidelines also include press release templates, sample educational emails that organizers can distribute to local legislators as well as fact sheets.

Shortly after Denver became the 1st county in the United States to decriminalize psilocybin mushrooms using a ballot initiative in 2019, activists from Decriminalize Nature in Oakland called for their city council to pass a motion that deprioritized the enforcement of laws against psychedelics including ibogaine and ayahuasca.  The local legislators approved the bill in a unanimous vote.

Following this win, the local Decriminalize Nature branch in Santa Cruz helped decriminalize entheogenic substances in the County as well as in Ann Arbor, Michigan. As all the council votes on these proposals have been unanimous, this shows the organization’s focus on educating legislators while also sharing personal journeys about the transformative effect these fungi and plants have had on supporters.

The group is just getting started though, with activists from more than 100 cities showing interest in following Decriminalize Nature’s footsteps. The released guidelines are a tool the organization is using to empower those activists.

The group also plans to continue with advocacy even after decriminalization has been attained in every state. They hope to do this using a follow-up legislation that would form a regulatory framework that allows for psychedelic healing ceremonies in the city.

In an additional note, residents of Oregon will be voting on a ballot initiative to legalize the use of psilocybin mushrooms for therapeutic purposes.

Experts say companies like Pure Extract Technologies Inc. feel encouraged when volunteers take up the mantle of educating communities about the immense benefits of psychedelics and why their continued criminalization isn’t warranted.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression

The FDA designation expands the drug’s potential patient pool tenfold, to an estimated 13 million…

1 day ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative

NRx Pharmaceuticals has filed a Citizen Petition with the FDA to remove benzethonium chloride from…

2 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

3 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

3 months ago